Barnes Larisa Aj, Leach Matthew, Anheyer Dennis, Brown Danielle, Carè Jenny, Lauche Romy, Medina Daen N, Pinder Tobey-Ann, Bugarcic Andrea, Steel Amie
University Centre for Rural Health, University of Sydney, Lismore, New South Wales, Australia.
National Centre for Naturopathic Medicine, Southern Cross University, Lismore, New South Wales, Australia.
Adv Integr Med. 2020 Dec;7(4):222-226. doi: 10.1016/j.aimed.2020.07.012. Epub 2020 Aug 13.
Based on the evidence identified in this rapid review, preparations and herbal complex preparations including may be a therapeutic option for treating early symptoms of respiratory tract infections. The best effectiveness for preparations has been proven for coughing, as an expectorant and to reduce the frequency and intensity of cough. Only weak evidence was found for all other researched symptoms. Both adults and children tolerate well. Currently, there is insufficient evidence to recommend the use of this supplement in the treatment or prevention of COVID-19. However, the current evidence justifies further research to better understand its applicability in coronavirus infections.
tCurrent evidence suggests may improve the frequency and intensity of cough associated with viral respiratory infection. The overall applicability of additional findings is limited by the poorly defined outcome measures employed. However, studies focused explicitly on expectoration did report an increased conversion from dry to productive cough, and an improvement in expectoration amount, consistency and colour. These effects may be explained by a related finding of reduced oropharyngeal congestion and improved inflammatory markers (erythrocyte sedimentation rate and c-reactive protein). A decrease in frequency of night cough and respiratory pain was also reported, as was improved sleep quality and reduced cough-related sleep disturbance.Some studies also measured general respiratory tract infection symptoms and identified clinical improvement or resolution of fever, fatigue, sore throat, sneezing, wheezing, nasal congestion, post-nasal drip and body-ache. A reduced need for antibiotic prescriptions was also identified. While not consistently reported, the majority of studies also found reduced the overall severity of viral bronchitis and related conditions. Tolerability was rated as between 'good' and 'high'. Adverse events were rare or non-existent in almost all studies, and those that were reported were defined as non-serious and not drug-related.
基于本次快速综述中确定的证据,包括[具体内容未给出]在内的制剂和草药复方制剂可能是治疗呼吸道感染早期症状的一种治疗选择。已证实该制剂在止咳方面效果最佳,可作为祛痰剂并减少咳嗽的频率和强度。对于所有其他研究的症状,仅发现了微弱的证据。成人和儿童对该制剂耐受性良好。目前,没有足够的证据推荐使用这种补充剂来治疗或预防新冠病毒。然而,目前的证据为进一步研究以更好地了解其在冠状病毒感染中的适用性提供了依据。
目前的证据表明[具体内容未给出]可能改善与病毒性呼吸道感染相关的咳嗽频率和强度。其他研究结果的总体适用性受到所采用的结局指标定义不明确的限制。然而,明确聚焦于咳痰的研究确实报告了干咳转为湿咳的转化率增加,以及咳痰量、质地和颜色的改善。这些效果可能由口咽充血减轻和炎症标志物(红细胞沉降率和C反应蛋白)改善这一相关发现来解释。还报告了夜间咳嗽频率和呼吸疼痛的降低,以及睡眠质量的改善和与咳嗽相关的睡眠障碍的减少。一些研究还测量了一般呼吸道感染症状,并确定发热、疲劳、喉咙痛、打喷嚏、喘息、鼻塞、鼻后滴漏和身体疼痛有临床改善或缓解。还发现抗生素处方需求减少。虽然并非一直有报告,但大多数研究还发现[具体内容未给出]降低了病毒性支气管炎及相关病症的总体严重程度。耐受性被评为“良好”至“高”。几乎所有研究中不良事件都很少见或不存在,报告的不良事件被定义为不严重且与药物无关。